Prophylactic Administration of Gypsophila oldhamiana Extract Restricts Acute Toxoplasma gondii Infection via the DC-IL-12-CD8⁺ T Cell Axis in a Murine Model Authors: Pureum Sun, Yeeun Kim, Juyoung Kim, In Soo Kim, Jaeyul Kwon, Winifrida Kidima, Jinki Yeom, Suyoung Choi, Bo-In Kwon Published: 2026 ABSTRACT IntroductionToxoplasma gondii (T. gondii) is a globally prevalent parasite that poses significant medical and veterinary challenges. Although current therapies such as pyrimethamine and sulfadiazine are effective, they often cause severe adverse effects, including myelosuppression, highlighting the need for safer and more effective alternatives. In this study, we evaluated the immunostimulatory and antiparasitic activities of three traditional herbal extracts, Stellaria dichotoma L. var. lanceolata Bge. (LDS), Stellaria aquaatic (SA) and Gypsophila oldhamiana (GO), in a murine model of T. gondii infection.MethodsTo investigate mechanisms, bone marrow-derived dendritic cells (BMDCs) were treated in vitro. For the in vivo model, C57BL/6 mice received oral extracts (100 mg/kg/day) for 13 days, starting six days prior to intraperitoneal challenge with T. gondii (ME49). Parasite burden and splenic immune profiles were analyzed at 7 days post-infection to assess acute-phase containment.ResultsThe findings of this study show that in vitro, GO extract promoted the maturation of BMDCs, significantly increasing CD11c+CD11blo mature dendritic cell subset and the expression of costimulatory molecules (CD40/CD80). Notably, GO simultaneously upregulated PD-L1 and PD-L2 on DCs, indicating a balanced Th1 response that prevents excessive immunopathology through checkpoint regulation while preserving strong effector functions. In vivo, GO-treated mice exhibited significantly lower splenic parasite loads than those in the control, LDS, or SA groups. GO significantly increased the frequency of IL-12-producing MHC II⁺ DCs and conventional DC type 1 (cDC1). This activation expanded IFN-γ -producing CD8⁺ and double-negative T cells, while NK cell responses were lower.ConclusionTherefore, our findings show that GO extract limits acute T. gondii infection by modulating the DC-IL-12-CD8⁺ T cell axis. This study provides a modern immunological basis for the traditional use of Yinchaihu and highlights GO as a promising plant-based candidate for preventing and maintaining immunological balance during intracellular parasitic challenges.Supplementary InformationThe online version contains supplementary material available at 10.1007/s11686-026-01296-z. Introduction Toxoplasma gondii (T. gondii) is a globally distributed apicomplexan parasite capable of infecting nearly all warm-blooded animals, including rodents, birds, and humans [1–3]. Classified as both a climate change–related disease and a zoonotic infection, T. gondii has become an important global public health concern [4]. Epidemiological studies estimate that approximately 30–50% of the world’s population has been exposed to or infected by T. gondii [5–8]. Human infection typically occurs through oral ingestion of oocysts or tissue cysts, after which the parasite disseminates from the gastrointestinal tract to the nervous and muscular systems [9]. While infection is usually asymptomatic in immunocompetent hosts, immunocompromised individuals may develop severe toxoplasmosis characterized by neurological symptoms, including headaches, disorientation, seizures, and retinal or cerebral lesions [10–12]. Moreover, chronic infection may contribute to persistent neuroinflammation, which has been associated with long-term neurological dysregulation [13]. Despite its high global prevalence and neurological implications, toxoplasmosis remains a neglected parasitic disease within current global health priorities [14]. Conventional chemotherapy, primarily involving the combination of pyrimethamine and sulfadiazine, targets rapidly replicating tachyzoites during acute infection, primarily by inhibiting parasite DNA replication [14]. Despite their efficacy in the acute phase, these regimens are frequently associated with severe adverse effects, most notably myelosuppression and hypersensitivity reactions, which often limit their clinical utility [15]. However, these regimens fail to eliminate chronic infection because tissue cyst–forming bradyzoites are highly resistant to conventional antibiotics [16]. These limitations underscore the urgent need for a prophylactic strategy to limit infection at its initial stage and prevent progression to the chronic phase. Given that tissue cyst formation arises from uncontrolled tachyzoite proliferation during the acute stage, establishing a primed immune state prior to infection is essential for effective containment. Accordingly, this study investigates whether specific herbal extracts can modulate innate and adaptive immunity to restrict parasite replication during acute infection. Given the limited evidence for plant-based treatments against toxoplasmosis, we examined the prophylactic immunomodulatory potential of three herbal extracts: Stellaria dichotoma L. var. lanceolata Bge. (LDS), Stellaria aquatica (SA), and Gypsophila oldhamiana (GO). According to the Korean Pharmacopoeia Outside Monograph for Herbal Medicines (4th edition), the traditional herb Yinchaihu (銀柴胡, Lanceolate Dichotomous Starwort) is defined as the dried root of either LDS or GO, both of which belong to the family Caryophyllaceae [17]. Although these species are used interchangeably in traditional markets, their distinct genera (Stellaria versus Gypsophila) imply differences in secondary metabolite composition and bioactivity, such as flavonoids and saponins [18, 19]. The wild resources of LDS have reached a stage of severe depletion due to over-harvesting. Consequently, current market surveys indicate that cultivated varieties and congeneric species, such as SA, are predominantly circulated as substitutes or adulterants [20]. Including SA in this study provides crucial scientific validation of whether these common market substitutes, particularly in the context of T.gondii infection, possess therapeutic potential comparable to that of the official monograph species [21]. The host immune defense against T. gondii relies primarily on professional antigen-presenting cells (APCs), such as dendritic cells (DCs), which initiate Th1-type cellular immunity [22–24]. During the critical early window of infection, rapid activation of the DC-mediated immune axis is vital to minimize delays in the onset of the adaptive response. This process depends on three kinds of signaling mechanisms: (1) Antigen recognition via TCR-MHC complex interaction, (2) Costimulatory signaling for T-cell expansion, and (3) Cytokine-driven differentiation, notably through IL-12 [25, 26]. Specifically, DC-derived IL-12 triggers NK cells to secrete IFN-γ, a pivotal cytokine that orchestrates the activation of macrophages and CD8⁺ T-cells. This downstream signaling subsequently upregulates cytolytic molecules, such as perforin and granzyme B, which are essential for eliminating intracellular parasites [27–31]. Additionally, bioactive constituents in herbal extracts may activate pattern recognition receptor (PRR)–mediated signaling in dendritic cells, resulting in increased IL‑12 secretion and promoting Th1-biased immune polarization [32, 33]. By potentizing these pathways through pre-treatment with bioactive constituents, we aimed to enhance the host’s ability to eliminate intracellular parasites before they can disseminate and establish chronic persistence. The purpose of this study is to evaluate the anti-parasitic and immunomodulatory effects of LDS, SA, and GO extracts specifically within a prophylactic-control framework. We focus on their ability to restrict. T. gondii by enhancing the DC-mediated Th1 immune response during the acute phase of infection. By comparing these extracts with conventional therapy, we aim to identify a potent, natural alternative that effectively limits parasite proliferation and modulates host defense while reducing toxicity, ultimately providing a strategic advantage in the early containment of Toxoplasma infection. Materials and Methods Preparation of Plant Extract To obtain standardized bioactive components for evaluating their immunomodulatory potential, the roots of each plant LDS, SA, and GO were processed. The roots of each plant were purchased from Kwang-myongdang Co. (Ulsan, Korea). Morphological identifications were authenticated by Dr. Bo-In Kwon. Each dried plant was refluxed in 70% ethanol (v/v) for 3 h, then concentrated under reduced pressure. In Vitro Studies: BMDC Maturation and Phenotypic Analysis BMDC Culture and Material Treatment To generate primary dendritic cells (DCs) for investigating the direct effects of the extracts on innate immune activation, BMDCs were generated from bone marrow cells collected from C57BL/6 mice, following established protocols [34]. Briefly, cells were cultured in cRPMI-1640 medium supplemented with 20 ng/mL of recombinant mouse GM-CSF (Granulocyte-macrophage colony-stimulating factor) for 6 days. BMDCs were maintained at 37 °C, 5% CO₂ humidified incubator, with a medium change on day 3. On day 6, harvested BMDCs were treated with LDS, SA, or GO extracts at non-cytotoxic concentrations (viability > 90%) to evaluate their immunomodulatory effects. On day 6, non-adherent BMDCs were harvested by gentle mechanical agitation and transferred to 24-well plates at a density of 5 × 105 cells/well for subsequent stimulation. To determine the optimal experimental concentrations, cells were initially treated with a range of LDS, SA, and GO concentrations (10, 20, 50, 100, 200, and 400 µg/mL). Following this screening, only concentrations that maintained cell viability of 90% or higher, as determined by flow cytometry, were selected for further immunological assays to ensure that the observed effects were not due to cytotoxicity. Based on this, 100 ug/mL was used for subsequent in vitro experiments. Vehicle (DMSO) control groups were maintained under identical incubator and media conditions to account for potential environmental variables. Flow Cytometry for BMDC Surface Marker Analysis To quantitatively evaluate the phenotypic changes and maturation status of BMDCs following extract treatment, surface marker expression was analyzed using flow cytometry. Cells were stained with fluorescently conjugated antibodies targeting differentiation markers and checkpoint ligands (Table 1). Dead cells were excluded from analysis using the Aqua Live/Dead staining kit (Invitrogen). When required, the Fixation/Permeabilization kit (BD Biosciences) was used to stain intracellular cytokines by permeabilizing membranes. Cells stained for surface markers and intracellular cytokines were immediately analyzed using flow cytometry (BD FACSCanto II, and all data were further analyzed using FlowJo software (BD Biosciences). In Vivo Studies: Prophylactic Efficacy in T. gondii-Infected Mice Animal Welfare and Ethical Considerations All mice were housed in a specific pathogen-free facility under controlled environmental conditions (temperature 22 ± 2 °C) with a 12-h light/dark cycle. Monthly microbiological monitoring was conducted to assess the animals’ health status. All mice had ad libitum access to sterilized food and water. All animal procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Chungnam National University (CNUH-2023-IA0108), and the study complied with the NIH Guide for the Care and Use of Laboratory Animals. In detail, to minimize animal suffering, humane endpoints were established based on clinical signs, including a body weight loss of > 20%, severe lethargy, or a lack of response to external stimuli. Animals reaching these criteria were immediately euthanized using gradual CO2 inhalation followed by cervical dislocation as a secondary confirmatory method. During the 7-day infection period, the health status and welfare of the mice were monitored at least twice daily by trained personnel. Environmental enrichment, including sterile nesting materials, was provided to reduce stress. All surgical procedures and spleen harvests were performed under deep anesthesia to eliminate pain. Parasite and Infection Animal Model To establish a standardized acute toxoplasmosis model for evaluating protective efficacy, the T. gondii ME49 strain was utilized. Bradyzoites were maintained in BALB/c mice by serial intraperitoneal (I.P.) inoculation. For the experimental infection model, 8-week-old C57BL/6 male mice were I.P. injected with 40 cysts. Extract Treatment for T. gondii Infected Mouse To evaluate the in vivo protective and immunomodulatory efficacy of herbal extracts during the early stage of T. gondii infection, an animal model was established using male C57BL/6 mice (8 weeks old). The extracts or vehicle (solvent control) were administered via oral gavage at 100 mg/kg/day. The treatment plan consisted of a 6-day pre-treatment followed by a 7-day post-treatment, for a total of 13 days. On day 0, mice were infected intraperitoneally (I.P.) with 40 brain cysts of the T. gondii ME49 strain. All mice were monitored daily for clinical signs. On day 7 post infection, the mice were sacrificed, and the spleens were harvested for further parasitological and immunological assessments. Intracellular Cytokine Staining (ICS) and Flow Cytometry for In Vivo Analysis To characterize the functional immune responses and cytokine secretion profiles of splenic immune cells, including DCs, T cells, and NK cells, during the acute phase, intracellular cytokine staining (ICS) was performed. On day 7 post-infection, mice were euthanized, and spleens were harvested and homogenized to obtain single-cell suspensions. Cells were washed and maintained in ice-cold FACS buffer (phosphate-buffered saline supplemented with 2 mM EDTA, 1% heat-inactivated FBS, and 0.02% sodium azide). For the detection of intracellular IL-12 and IFN-γ, splenocytes were cultured in medium containing 10 ug/mL brefeldin A (BFA, Sigma-Aldrich). To specifically assess the ex vivo IFN- γ production capacity of T cells, splenocytes were cultured at a density of 5 × 106 cells/mL in cRPMI-1640 medium supplemented with 1 ug/mL anti-CD3e (145-2C11; BD Biosciences) and 10 ug/mL BFA for 4 h at 37 °C. Following incubation, cells were first stained with fluorescently conjugated surface antibodies to identify NK cells (innate immunity), DCs (APCs), and T cells (adaptive immunity), as detailed in Table 1. After surface staining, cells were fixed and permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) according to the manufacturer’s instructions. Subsequently, intracellular staining was performed for IL-12 and IFN-γ. Stained cells were analyzed using flow cytometry to measure the frequency and expression levels of cytokines in each immune cell subset. Table 1Detailed information on antibodies used for flow cytometry analysis of various immune cell subsetsCell typeTargetFluorochromeVendorCloneCat#BMDCsPD-L2FITCThermo Fisher Scientific12211-9972-85PD-L1PEBD BiosciencesMIH5558091MHC IIPerCP-Cy™5.5BD BiosciencesM5/114.15.2562363CD80PE-Cy7eBioscience16-10A125-0801-82CD11cAPCTONBO BiosciencesN41820-0114-U025CD11bAPC-Cy7BioLegendM1/70101226CD40V450BD Biosciences3/23562846DCsIL-12FITCBD BiosciencesC15.6562564MHC IIPerCP-Cy™5.5BD BiosciencesM5/114.15.2562363CD11cAPCTONBO BiosciencesN41820-0114-U025CD8APC-H7BD Biosciences53-6.7560182T cellsCD3PEBioLegend17A2110206IFN-γPE-Cy™7BD BiosciencesXMG1.2557649CD8APC-H7BD Biosciences53-6.7560182CD4V450BD BiosciencesGK1.5562891NK cellsNK1.1PEBD BiosciencesPK136557391MHC IIPerCP-Cy™5.5BD BiosciencesM5/114.15.2562363IFN-γPE-Cy™7BD BiosciencesXMG1.2557649TCR-βAPCBioLegendH57-597109219F4/80V450BioLegendBM8123137Live cellsLIVE/DEAD™ Fixable Aqua Dead Cell StainV500Invitroge–L34966Kit, for 405 nm excitationBMDC, bone marrow-derived dendritic cell; DC, dendritic cell; NK, natural killer; MHC II, major histocompatibility complex class II; IL-12, interleukin-12; PD-L1/2, programmed death-ligand 1/2; IFN-γ, interferon-gamma; TCR-β, T-cell receptor beta. Detailed information on antibodies used for flow cytometry analysis of various immune cell subsets BMDC, bone marrow-derived dendritic cell; DC, dendritic cell; NK, natural killer; MHC II, major histocompatibility complex class II; IL-12, interleukin-12; PD-L1/2, programmed death-ligand 1/2; IFN-γ, interferon-gamma; TCR-β, T-cell receptor beta. Quantification of Parasite gDNA Using Real-Time Quantitative PCR (qRT-PCR) for In Vivo Experiment To determine the efficacy of the extracts in restricting parasite replication in host tissues, the absolute amount of T. gondii genomic DNA (gDNA) in the spleen was measured. Total gDNA was extracted from the infected mouse spleen cells to quantify the parasite load. Tissues were homogenized, and gDNA was isolated using the G-DEXTM LLC Genomic DNA Extraction Kit (Intron Biotech, Korea) according to the manufacturer’s instructions. To ensure the quality of the template DNA, the concentration and purity of the extracted gDNA were assessed using a spectrophotometer (NanoDrop™, Thermo Fisher Scientific). Only samples with an A260/A280 ratio between 1.8 and 2.0 were utilized for subsequent assays. Absolute quantification of T. gondii B1 DNA (pg/spleen) was performed using the gold standard primers: TOXO-F (5ʹ-TCCCCTCTGCTGGCGAAAAGT-3ʹ) and TOXO-R (5ʹ-AGCGTTCGTGGTCAACTATCGATTG-3ʹ) (IDT). Statistical Analysis All experimental data were presented as the mean ±standard deviation (SD) of at least three independent replicates. Statistical significance between multiple groups was determined using one-way analysis of variance (ANOVA) followed by Dunnett’s post-hoc multiple comparison test versus the corresponding DMSO control. For all quantitative assays, including qRT-PCR and flow cytometry, the reliability of the measurements was verified, with an inter-assay coefficient of variation (CV%) of < 10%. All statistical analyses and graphical representations were performed using GraphPad Prism software (Ver. 9, GraphPad Software, CA, USA). Results Identification of BMDC Subpopulations at Distinct Maturation Stages To characterize the maturation stages of the BMDCs subpopulation, live cell populations were divided into three distinct subpopulations: CD11cloCD11blo (cyan), CD11c+CD11bhi (orange), and CD11c+CD11blo (red) after live cell gating (Fig. 1A). CD11cloCD11blo subpopulation exhibited an immature phenotype, displaying the lowest basal expression of MHC II and costimulatory molecules (CD40 and CD80). CD11c+ CD11bhi subpopulation exhibited an intermediate maturation state, characterized by the highest expression of PD-L1, CD11c, and CD11b. In contrast, the CD11c+CD11blo subpopulation was identified as the most mature DC phenotype, exhibiting high MHC II and CD40/CD80 expression and significantly lower PD-L1 expression than the CD11c+CD11bhi Subpopulation (Fig. 1B). Fig. 1GO extract induces phenotypic maturation and population shifts in BMDCs. A Flow cytometric gating strategy for BMDC subpopulations based on CD11c and CD11b: CD11cloCD11blo (immature, cyan), CD11c+ CD11bhi (intermediate, orange), and CD11c+ CD11blo (mature, red). B Representative histograms and MFI summary of maturation and checkpoint markers across the three subsets. C Relative frequencies of each subpopulation following treatment with GO extract (10, 20, 50,100 ug/mL) for 24 h. D Comparison of surface marker MFIs (CD11c, CD11b, MHC II, CD40, CD80, and PD-L1) in total CD11c+ cells after treatment with DMSO, LDS, SA, or GO. Data are expressed as mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA with Dunnett’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. DMSO control (colour figure online) GO extract induces phenotypic maturation and population shifts in BMDCs. A Flow cytometric gating strategy for BMDC subpopulations based on CD11c and CD11b: CD11cloCD11blo (immature, cyan), CD11c+ CD11bhi (intermediate, orange), and CD11c+ CD11blo (mature, red). B Representative histograms and MFI summary of maturation and checkpoint markers across the three subsets. C Relative frequencies of each subpopulation following treatment with GO extract (10, 20, 50,100 ug/mL) for 24 h. D Comparison of surface marker MFIs (CD11c, CD11b, MHC II, CD40, CD80, and PD-L1) in total CD11c+ cells after treatment with DMSO, LDS, SA, or GO. Data are expressed as mean ± SD (n = 3). Statistical significance was determined by one-way ANOVA with Dunnett’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. DMSO control (colour figure online) GO Extract Facilitates the Expansion and Functional Activation of Mature BMDCs GO treatment induced a dose-dependent redistribution of BMDC subpopulations, significantly increasing the mature CD11c+CD11blo subset while decreasing the CD11c+ CD11bhi population (Fig. 1C). These changes were observed alongside a cell viability of > 90% across all groups (Supplementary Fig. 1A). Within the mature CD11c+CD11blo subset, GO treatment increased the MFI of CD40 and CD80 in a dose-dependent manner (Fig. 1D). This was accompanied by reduced CD11c expression and increased MFI of PD-L1 and PD-L2 (Supplementary Fig. 1B). Further analysis of the total MHCII+CD11c+ population showed that GO treatment dose-dependently enhanced the MFI of CD40 and CD80, while the MFI of CD11b and CD11c decreased (Fig. 2A–D). Additionally, GO treatment increased the MFI of PD-L1 and PD-L2, whereas no significant change was observed in MHCII MFI (Fig. 2E–G). Fig. 2Dose-dependent effects of GO extract on maturation and checkpoint markers in the mature BMDC subpopulation. A–G Mean fluorescence intensity (MFI) of CD40 (A), CD80 (B), CD11b (C), CD11c (D), PD-L1 (E), PD-L2 (F), and MHC II (G) was analyzed specifically in the MHC II+ CD11c+ mature BMDC subpopulation. Cells were treated with four increasing concentrations of DMSO, LDS, SA, or GO extract for 24 h. Among the tested extracts, GO treatment significantly upregulated CD40, PD-L1, and PD-L2, while significantly decreasing CD11b and CD11c expression at the highest dose. Data are presented as the mean ± SD of three independent experiments (n = 3). Statistical significance was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. DMSO control Dose-dependent effects of GO extract on maturation and checkpoint markers in the mature BMDC subpopulation. A–G Mean fluorescence intensity (MFI) of CD40 (A), CD80 (B), CD11b (C), CD11c (D), PD-L1 (E), PD-L2 (F), and MHC II (G) was analyzed specifically in the MHC II+ CD11c+ mature BMDC subpopulation. Cells were treated with four increasing concentrations of DMSO, LDS, SA, or GO extract for 24 h. Among the tested extracts, GO treatment significantly upregulated CD40, PD-L1, and PD-L2, while significantly decreasing CD11b and CD11c expression at the highest dose. Data are presented as the mean ± SD of three independent experiments (n = 3). Statistical significance was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. DMSO control Regarding cell frequencies, most markers remained stable across treatments, except for a dose-dependent increase in PD-L1⁺ frequency in the SA group (Fig. 3F) and a slight decrease in the overall MHCII+ frequency in the GO group (Fig. 3E). However, within the CD11c+MHCII+CD40+ population, GO treatment specifically increased the frequency of the CD80+ subset (Supplementary Fig. 3). Fig. 3Alterations in the frequency of maturation and checkpoint markers in BMDCs. A–G The percentage of cells expressing CD40 (A), CD80 (B), CD11b (C), CD11c (D), PD-L1 (E), PD-L2 (F), and MHC II (G) was analyzed within the total MHC II+ CD11c+ BMDC population. Cells were treated with increasing concentrations of DMSO, LDS, SA, or GO extract for 24 h. While most maturation markers remained stable in frequency, SA treatment induced a dose-dependent increase in the frequency of PD-L1 + cells (E). Conversely, GO treatment resulted in a slight but significant decrease in the overall MHC II+ cell frequency at the highest concentration (F). Data represent the mean ± SD from three independent experiments (n = 3). Statistical significance was assessed by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05 vs. DMSO control Alterations in the frequency of maturation and checkpoint markers in BMDCs. A–G The percentage of cells expressing CD40 (A), CD80 (B), CD11b (C), CD11c (D), PD-L1 (E), PD-L2 (F), and MHC II (G) was analyzed within the total MHC II+ CD11c+ BMDC population. Cells were treated with increasing concentrations of DMSO, LDS, SA, or GO extract for 24 h. While most maturation markers remained stable in frequency, SA treatment induced a dose-dependent increase in the frequency of PD-L1 + cells (E). Conversely, GO treatment resulted in a slight but significant decrease in the overall MHC II+ cell frequency at the highest concentration (F). Data represent the mean ± SD from three independent experiments (n = 3). Statistical significance was assessed by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05 vs. DMSO control GO Extract Reduces Splenic Parasite Load and Increases Mature DC Frequency In Vivo To evaluate the prophylactic efficacy of the extracts, we established a murine infection model following a prophylactic-control framework. As detailed in the methods, extracts (100 mg/kg) were administered orally for 13 consecutive days, beginning six days prior to the T. gondii challenge (Fig. 4A). During the 6-day pre-treatment period, no abnormal clinical signs or significant body weight loss were observed, indicating the initial safety of all extract administrations. On day 0, each mouse was challenged with 40 cysts of the T. gondii ME49 strain via I.P. injection. The animals were euthanized on day 7 post-infection (dpi), a time point that marks the acute phase of infection. This timing was chosen to observe the immediate host immune response, especially the DC-mediated Th1 axis, at the peak of parasite replication and before the transition to chronic tissue cysts (bradyzoites). Reduction of Splenic Parasite Load by GO Extract The primary outcome of the prophylactic intervention was a significant reduction in systemic parasite load. Quantification of T. gondii genomic DNA (gDNA) in the spleen via qRT-PCR revealed that GO-treated mice exhibited a significant reduction in parasite gDNA levels compared to the DMSO, LDS, and SA groups (***p < 0.001; Fig. 4B). Fig. 4GO extract reduces splenic parasite load and enhances DC activation in a murine model of acute toxoplasmosis. A Experimental scheme for the prophylactic administration of herbal extracts (100 mg/kg) and T. gondii infection (40 cysts, I.P.). B Quantification of T. gondii genomic DNA in the spleen at 7 dpi via qRT-PCR. The points mean each sample points (n = 5–8) C Flow cytometric gating strategy for identifying splenic dendritic cell (DC) subpopulations and their intracellular IL-12 expression. D–F Frequency of total CD11c+ DCs (D), MHC II+ CD11c+ DCs (E), and CD8+ CD11c+ DCs (F) in the spleen. G–I Percentage of IL-12-producing cells within the total CD11c+ population (G), MHC II+ CD11c+ population (H), and CD11c+ CD8+ (cDC1) population (I). Data are presented as the mean ± SD (n = 3–5). Statistical significance was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. DMSO control GO extract reduces splenic parasite load and enhances DC activation in a murine model of acute toxoplasmosis. A Experimental scheme for the prophylactic administration of herbal extracts (100 mg/kg) and T. gondii infection (40 cysts, I.P.). B Quantification of T. gondii genomic DNA in the spleen at 7 dpi via qRT-PCR. The points mean each sample points (n = 5–8) C Flow cytometric gating strategy for identifying splenic dendritic cell (DC) subpopulations and their intracellular IL-12 expression. D–F Frequency of total CD11c+ DCs (D), MHC II+ CD11c+ DCs (E), and CD8+ CD11c+ DCs (F) in the spleen. G–I Percentage of IL-12-producing cells within the total CD11c+ population (G), MHC II+ CD11c+ population (H), and CD11c+ CD8+ (cDC1) population (I). Data are presented as the mean ± SD (n = 3–5). Statistical significance was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. DMSO control Activation Profile and IL-12 Production of Splenic Dendritic Cells To elucidate the underlying anti-parasitic immune mechanisms, we analyzed splenic immune populations via flow cytometry (Fig. 4C). Consistent with our in vitro findings, the frequency of CD11c+MHCII+ DCs was significantly increased in GO-treated mice (*p < 0.05; Fig. 4D, E). Intracellular cytokine staining also showed that GO treatment significantly increased the proportion of IL-12-producing CD11c+ MHCII+ DCs and major IL-12-producing CD11c+ CD8+ Conventional dendritic cell type 1 (cDC1) (Fig. 4G–I). While the total frequency of CD11c+ CD8+ DCs was significantly lower in the GO-treated group (*p < 0.001, Fig. 4F), the percentage of IL-12-producing cells within this specific CD11c+CD8 + cDC1 subset was significantly enhanced (*p < 0.05; Fig. 4I). GO Treatment Increases CD8+ T-Cell Frequency and IFN-γ Production To evaluate adaptive immune responses, splenic CD3+ T-cell populations were analyzed by flow cytometry (Fig. 5A). CD3+ T cells were categorized into CD4+CD8− (helper), CD4−CD8+ (cytotoxic), and CD4−CD8− (double-negative, DN) subsets. The frequencies of all T cell subsets remained stable across the LDS and SA treatment groups (Fig. 5B–C). Whereas the GO treatment group significantly decreased CD4+CD8− helper T cells (*p < 0.05; Fig. 5B) and expanded the CD4−CD8− DN T cell (*p < 0.05; Fig. 5C) and the CD4−CD8+ cytotoxic T-cell population compared to the control (**p < 0.01; Fig. 5D). IFN-γ production within these T-cell subsets was quantified to assess functional activity. Notably, the proportions of IFN-γ-producing cells within the CD4+ CD8− subpopulations did not differ significantly between the GO-treated and control groups (Fig. 5E). In contrast, GO treatment resulted in a significant increase in the proportion of IFN-γ-producing cells within the CD4−CD8− DN (***p < 0.001; Fig. 5F). T cells and CD4-CD8 + T-cell subset (**p < 0.01; Fig. 5G). Fig. 5Inhibitory effects were observed during acute inflammation induced by the T. gondii ME49 strain, associated with increased CD8 + T cells and improved IFN-γ production. A Gating strategy for distinguishing T cells in the T. gondii acute infection mouse model. CD4 was used as a helper T cell marker, while CD8 was chosen as a cytotoxic T cell marker. B–D The CD4−CD8−, CD4+CD8−, and CD4−CD8+ populations were measured in mouse splenocytes treated with vehicle, LDS, SA, or GO. E–G IFN-γ cytokine production capacity levels were measured in CD4−CD8−, CD4+CD8−, and CD4−CD8+ splenocytes treated with vehicle, LDS, SA, or GO. Statistical significance was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. DMSO control Inhibitory effects were observed during acute inflammation induced by the T. gondii ME49 strain, associated with increased CD8 + T cells and improved IFN-γ production. A Gating strategy for distinguishing T cells in the T. gondii acute infection mouse model. CD4 was used as a helper T cell marker, while CD8 was chosen as a cytotoxic T cell marker. B–D The CD4−CD8−, CD4+CD8−, and CD4−CD8+ populations were measured in mouse splenocytes treated with vehicle, LDS, SA, or GO. E–G IFN-γ cytokine production capacity levels were measured in CD4−CD8−, CD4+CD8−, and CD4−CD8+ splenocytes treated with vehicle, LDS, SA, or GO. Statistical significance was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05, **P < 0.01, ***P < 0.001 vs. DMSO control Characterization of Splenic NK Cell Responses at the Peak of Acute Infection To examine innate lymphoid cell responses during the acute phase of infection, we analyzed the frequency and functional activity of splenic NK cells at 7 dpi (Fig. 6A). Following the exclusion of F4/80+ macrophages, splenocytes were categorized into TCR-β+ NK1.1− (Gate 1), TCR-β−NK1.1− (Gate 2), and TCR-β− NK1.1+(Gate 3) populations. The frequency of these three subsets was comparable across all treatment groups (Fig. 6B). Functional assessment via intracellular cytokine staining showed that at 7 dpi, the frequency of IFN-γ-producing cells within the NK cell population (Gate 3) was significantly lower in the GO and SA groups compared to the DMSO control (*p < 0.05; Fig. 6C). In Gate 1, SA treatment also led to a significant reduction in the proportion of IFN-γ-producing cells (**p < 0.01), whereas no significant differences were observed in the GO-treated group for these populations (Fig. 6C). Fig. 6Characterization of splenic NK cell and TCR-beta+ population responses during acute T. gondii infection. A Flow cytometric gating strategy for classifying F4/80- splenocytes into three subpopulations based on TCR-β and NK1.1 expression: Gate 1 (TCR-β+NK1.1−; T cells), Gate 2 (TCR-β−NK1.1−; double-negative population), and Gate 3 (TCR-β−NK1.1+; NK cells). B Relative frequencies of each gate within the F4/80−population across the treatment groups (DMSO, LDS, SA, and GO). C Intracellular IFN-γ production levels in Gates 1, 2, and 3. While the frequencies of these subsets remained comparable across groups, GO and SA treatment significantly reduced the proportion of IFN-γ-producing cells within the NK cell population (Gate 3) at 7 dpi. Data represent the mean ± SD (n = 8–12). Statistical significance was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05, **P < 0.01 vs. DMSO control Characterization of splenic NK cell and TCR-beta+ population responses during acute T. gondii infection. A Flow cytometric gating strategy for classifying F4/80- splenocytes into three subpopulations based on TCR-β and NK1.1 expression: Gate 1 (TCR-β+NK1.1−; T cells), Gate 2 (TCR-β−NK1.1−; double-negative population), and Gate 3 (TCR-β−NK1.1+; NK cells). B Relative frequencies of each gate within the F4/80−population across the treatment groups (DMSO, LDS, SA, and GO). C Intracellular IFN-γ production levels in Gates 1, 2, and 3. While the frequencies of these subsets remained comparable across groups, GO and SA treatment significantly reduced the proportion of IFN-γ-producing cells within the NK cell population (Gate 3) at 7 dpi. Data represent the mean ± SD (n = 8–12). Statistical significance was determined by one-way ANOVA followed by Dunnett’s post-hoc test. *P < 0.05, **P < 0.01 vs. DMSO control Discussion The primary objective of this study was to evaluate the immunomodulatory and antiparasitic potential of three Caryophyllaceae species, LDS, SA, and GO, against T. gondii. Our findings demonstrate that GO extract exhibits superior efficacy in restricting parasite infection during the acute phase by selectively potentiating the DC-IL-12-T cell axis [35]. The distinct potency of GO relative to LDS and SA is largely attributable to its high content of triterpenoid saponins [36–40]. These molecules are known to disrupt parasite membrane integrity by altering fluidity and permeability [41, 42]. Furthermore, they stimulate cytokine production and macrophage activation, thereby enhancing innate immunity and parasite clearance [43, 44]. Given that saponins can act as potent adjuvants triggering pattern recognition receptors, the protective mechanism of GO in our model appears to be primarily driven by the functional maturation of dendritic cells (DCs). As established by Hou et al., DC-intrinsic MyD88 signaling is essential for the initiation of early IL-12 production and host survival [45]. In alignment with this, our study demonstrated that GO treatment significantly increased the frequency of IL-12-producing MHC II⁺ DCs, thereby strengthening both antigen presentation and costimulatory signaling. Although the C15.6 antibody utilized in our ICS analysis targets the p40 subunit shared by both IL-12 and IL-23, the observed immunological shift characterized by CD8+ T cell expansion and IFN-γ production strongly suggests that the bioactive IL-12p70 heterodimer is the primary driver of GO-mediated protection. Given that IL-12p70 is the indispensable cytokine for Th1 differentiation and parasite containment in acute toxoplasmosis, our findings provide a consistent biological narrative of the DC-IL-12-T cell axis. This DC-derived IL-12 provides the critical “Signal 3” for T cell differentiation and activation, driving the expansion of IFN-γ-producing CD8⁺ T cells, which subsequently release cytolytic molecules, such as perforin, to target intracellular parasites [46–48]. As indicated by studies in β2m-deficient mice, NK cells can provide essential IFN-γ-mediated compensation in the absence of robust T cell responses [49]. However, in the context of GO treatment, our data suggest that the DC-CD8+ T-cell axis serves as the dominant pathway for acute-phase control. In traditional East Asian medicine, Yinchaihu (銀柴胡) has been traditionally prescribed to “clear deficiency heat” (虛熱), a pathological state characterized by low-grade fever and impaired host resistance that often follows an unresolved febrile illness [17, 50]. Clinically, Yinchaihu is favored for its ability to restore immunological balance without the side effects of excessive cooling or immunosuppression, a principle known as “clearing heat without damaging vital energy (正氣)” [50, 51]. From a modern immunological perspective, this traditional concept aligns well with our acute-phase findings. In the present study, GO selectively enhanced DC-mediated IL-12 production and promoted CD8⁺ cytotoxic T-cell immunity, the primary defense against acute T. gondii infection [52], while simultaneously upregulating co-expression of PD-L1 and PD-L2 [53]. This unique immune profile suggests that GO does not simply trigger an indiscriminate inflammatory surge, rather, it orchestrates a calibrated Th1 response. By inducing regulatory ligands alongside potent effector functions during the 7-dpi acute phase, GO may prevent the excessive immunopathology that typically leads to host exhaustion and chronic persistence. Thus, the clearing deficiency heat property of Yinchaihu can be interpreted as a strategic intervention that stabilizes the host during the initial parasitic challenge. By maintaining immunological homeostasis early on, GO provides a scientific basis for the historical use of Yinchaihu in preventing the consumptive states associated with lingering infections. Our results highlight GO as a promising prophylactic botanical source that bridges innate and adaptive immunity, ensuring early containment while preserving host physiological integrity. GO extract represents a potential prophylactic agent against T. gondii, addressing current limitations in immunomodulatory therapies [54, 55]. By selectively potentiating DC-mediated Th1 immunity during the acute phase, GO may inhibit the transition to chronic persistence [46, 56]. Given the plant-derived prophylactic intervention’s low toxicity and defined mechanism, this botanical extract is a candidate for clinical translation, particularly for immunocompromised populations. Although promising, two critical next steps are required for clinical translation. First, chronic-phase validation (e.g., 30 dpi brain cyst burden) will confirm if acute efficacy translates to long-term protection. Second, fractionation of active triterpenoid saponins will elucidate the molecular basis of GO’s superiority over LDS and SA. These targeted advancements, alongside its low toxicity (viability > 90%, Supplementary Fig. S1A), position GO as a leading Yinchaihu derivative for immunocompromised patients. In conclusion, our findings suggest that GO extract is a notable candidate among Caryophyllaceae species for enhancing host defense against T. gondii. By modulating the DC-IL-12-T cell axis, GO extract facilitates early containment of the parasite during the acute phase. These results provide a scientific basis for the traditional medicinal use of Yinchaihu and highlight GO as a potential plant-derived prophylactic strategy. This study offers valuable insights into the use of natural immunomodulators to bridge innate and adaptive immunity while maintaining immunological homeostasis during intracellular parasitic challenges. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1